Nexavar News and Research

RSS
Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

Research on rare cancers

Research on rare cancers

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas, AVEO enter development, commercialization agreement for tivozanib

Study: Overexpression of EZH2 protein promotes breast cancer progression

Study: Overexpression of EZH2 protein promotes breast cancer progression

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Novel adenovirus-based gene therapy for renal cell carcinoma

Novel adenovirus-based gene therapy for renal cell carcinoma

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH

Promising Phase 2 data of perifosine in CLL and HL presented at 52nd ASH